$ 10.63 Billion in Sales Expected for Thermo Fisher Scientific Inc. (NYSE: TMO) This Quarter

Brokerages expect that Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating) will announce $ 10.63 billion in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Thermo Fisher Scientific’s earnings. The lowest sales estimate is $ 10.38 billion and the highest is $ 10.95 billion. Thermo Fisher Scientific posted sales of $ 9.91 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.3%. The business is scheduled to report its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Thermo Fisher Scientific will report full year sales of $ 42.15 billion for the current fiscal year, with estimates ranging from $ 41.99 billion to $ 42.55 billion. For the next financial year, analysts forecast that the firm will report sales of $ 44.69 billion, with estimates ranging from $ 43.90 billion to $ 45.60 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE: TMO – Get Rating) last issued its quarterly earnings data on Wednesday, February 2nd. The medical research company reported $ 6.54 EPS for the quarter, topping analysts’ consensus estimates of $ 5.22 by $ 1.32. Thermo Fisher Scientific had a net margin of 19.70% and a return on equity of 26.34%. The firm had revenue of $ 10.70 billion for the quarter, compared to analyst estimates of $ 9.25 billion. During the same quarter in the previous year, the business posted $ 7.09 EPS. The firm’s revenue was up 1.4% compared to the same quarter last year.

A number of equities research analysts have recently issued reports on TMO shares. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $ 700.00 to $ 605.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 3rd. Barclays assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 26th. They issued an “overweight” rating and a $ 700.00 target price on the stock. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $ 609.00 price objective for the company. in a research report on Monday, January 24th. StockNews.com assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $ 718.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $ 645.31.

Shares of Thermo Fisher Scientific stock opened at $ 568.90 on Wednesday. The firm has a market cap of $ 222.69 billion, a PE ratio of 29.25, a price-to-earnings-growth ratio of 1.80 and a beta of 0.82. The firm’s 50-day simple moving average is $ 565.46 and its 200-day simple moving average is $ 598.45. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.12 and a current ratio of 1.50. Thermo Fisher Scientific has a 1 year low of $ 438.72 and a 1 year high of $ 672.34.

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 14th. Investors of record on Wednesday, March 16th were paid a dividend of $ 0.30 per share. The ex-dividend date of this dividend was Tuesday, March 15th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $ 0.26. This represents a $ 1.20 annualized dividend and a yield of 0.21%. Thermo Fisher Scientific’s dividend payout ratio is currently 6.17%.

In related news, Director Jim P. Manzi sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, February 14th. The shares were sold at an average price of $ 563.95, for a total value of $ 845,925.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.44% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mizuho Securities Co. Ltd. grew its stake in Thermo Fisher Scientific by 200.0% in the 3rd quarter. Mizuho Securities Co. Ltd. now owns 45 shares of the medical research company’s stock valued at $ 26,000 after buying an additional 30 shares during the last quarter. Widmann Financial Services Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $ 26,000. Core Alternative Capital bought a new stake in Thermo Fisher Scientific in the 3rd quarter valued at $ 27,000. Mystic Asset Management Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $ 29,000. Finally, Lee Financial Co bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $ 32,000. Institutional investors own 86.17% of the company’s stock.

Thermo Fisher Scientific Company Profile (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE: TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.


Leave a Reply

Your email address will not be published.

Back to top button